Summary

Hemato Oncology Testing Market Summary

The global hemato oncology testing market size was estimated at USD 3.60 billion in 2024 and is projected to reach USD 7.44 billion by 2030, growing at a CAGR of 12.99% from 2025 to 2030. Hemato oncology is associated with the treatment, diagnosis, and prevention of blood-related cancers and diseases.

Increasing prevalence of lymphoma & myeloma, growing demand for personalized therapy, availability of advanced molecular techniques for hemato-oncology diagnostics, and increasing drug-diagnostics co-development are some of the major factors anticipated to boost the growth of the market during the forecast period. The rapid evolution of molecular diagnostics has transformed the landscape of hemato-oncology, offering precise and personalized approaches for the detection, diagnosis, prognosis, and treatment of various blood cancers. These cutting-edge techniques have significantly improved the understanding of disease biology and therapeutic response, leading to better patient outcomes and more efficient clinical workflows.

Molecular diagnostics in hematologic malignancies often rely on methods like real-time PCR, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS) to detect specific genetic alterations. For instance, chronic myeloid leukemia (CML) is routinely diagnosed using PCR-based tests targeting the BCR::ABL1 fusion gene or FISH assays. Standardization of BCR/ABL measurement internationally has facilitated easier and more accurate diagnosis of CML across laboratories. Similarly, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) benefit from molecular diagnostics, with NGS panels enabling the identification of multiple gene mutations simultaneously, including FLT3-ITD, NPM1, and TP53, which are critical for risk stratification and treatment selection. In lymphomas, techniques like T-cell clonality assays, targeted FISH, and IgVH analysis are widely employed, while the JAK2 V617F mutation serves as a critical marker for diagnosing polycythemia vera in high-risk patients.

Recent advancements have introduced more sophisticated tools such as single-cell sequencing, optical genome mapping (OGM), and long-read sequencing. Single-cell sequencing provides unprecedented resolution at the cellular level, offering insights into clonal diversity and tumor evolution. OGM, as demonstrated in a recent study published in The Journal of Molecular Diagnostics, enables comprehensive cytogenomic profiling of tumors, including multiple myeloma, by efficiently identifying structural variants and copy number changes even in low-yield cell populations. This pan-genomic approach reduces the need for separate, marker-specific tests, streamlining workflows and improving diagnostic accuracy. The study at Lille University Hospital confirmed that OGM can reduce the number of cells required for complete genomic profiling, showing 93% concordance with traditional FISH on five tested markers and identifying over 22 additional genomic variants of interest.

In 2024, Oxford Gene Technology (OGT) introduced the SureSeq Myeloid Fusion Panel, a groundbreaking RNA-based NGS tool designed for the comprehensive identification of fusion genes in AML. This panel, developed in collaboration with leading myeloid cancer experts, covers over 30 key disease-associated fusions, including KMT2A and MECOM, and employs a partner-gene agnostic approach to detect rare and novel fusions in a single assay. The integration of this panel into end-to-end NGS workflows has significantly enhanced the ability to classify samples, reducing the need for extensive bioinformatics resources and improving turnaround times in clinical laboratories.

Moreover, long-read sequencing technologies, such as those developed by Pacific Biosciences and Oxford Nanopore, are revolutionizing the field by providing complete, error-free readouts of complex genomic regions. These platforms are overcoming the limitations of short-read NGS, enabling the detection of structural variants, complex rearrangements, and copy number changes with unparalleled precision.

Collectively, these advanced molecular technologies are reshaping the diagnostic landscape in hemato-oncology, providing clinicians with powerful tools for personalized medicine. The continuous innovation in this space promises to further enhance the accuracy, speed, and cost-effectiveness of cancer diagnostics, ultimately leading to better patient outcomes and more personalized treatment strategies.

In addition, lymphoma and myeloma are among the most common and clinically significant hematologic malignancies in the United States, contributing significantly to the overall cancer burden.

Global Hemato Oncology Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the market trends in each of the sub-markets from 2018 to 2030. For this study, Grand View Research has segmented the global hemato oncology testing market report based on cancer, product, technology, end use, and region:

• Cancer Outlook (Revenue, USD Million, 2018 - 2030)
• Leukemia
o Acute Myeloid Leukemia (AML)
o Acute Lymphocytic Leukemia (ALL)
o Chronic Lymphocytic Leukemia
o Chronic Myeloid Leukemia
• Lymphoma
o Non-Hodgkin Lymphoma
o Hodgkin Lymphoma
• Myeloproliferative Neoplasms
o Polycythemia vera (PV)
o Essential thrombocythemia (ET)
o Myelofibrosis (MF)
• Other Cancers
• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Assay Kits and Reagents
• Services
• Technology Outlook (Revenue, USD Million, 2018 - 2030)
• PCR
o Real-time qPCR
o Digital PCR
• IHC
• NGS
• Cytogenetics
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Academic and Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
o U.S
o Canada
o Mexico
• Europe
o UK
o Germany
o France
o Italy
o Spain
o Russia
o Denmark
o Sweden
o Norway
• Asia Pacific
o India
o China
o Japan
o Australia
o Singapore
o South Korea
o Thailand
• Latin America
o Argentina
o Brazil
• Middle East & Africa
o Saudi Arabia
o UAE
o South Africa
o Kuwait

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.7.1. Commodity flow analysis
1.7.2. Global Market: CAGR Calculation
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Hemato oncology testing Market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market
3.1.2. Ancillary Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of lymphoma & myeloma
3.2.1.2. Growing demand for personalized therapy
3.2.1.3. Availability of advanced molecular techniques for hemato oncology diagnostics
3.2.1.4. Increasing drug-diagnostics co-development
3.2.2. Market Restraint Analysis
3.2.2.1. Favorable reimbursement scenario
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Hemato oncology testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitution
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal Landscape
3.3.2.2. Economic and Social Landscape
3.3.2.3. Technological landscape
3.3.2.4. Environmental Landscape
3.3.3. Regulatory Framework
Chapter 4. Hemato oncology testing Market: Cancer Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Hemato oncology testing Market Cancer Movement Analysis
4.3. Hemato oncology testing Market Size & Trend Analysis, By Cancer, 2018 - 2030 (USD Million)
4.4. Leukemia
4.4.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Acute Myeloid Leukemia (AML)
4.4.2.1. Acute Myeloid Leukemia (AML) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.2. Acute Lymphocytic Leukemia (ALL)
4.4.2.2.1. Acute Lymphocytic Leukemia (ALL) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.3. Chronic Lymphocytic Leukemia
4.4.2.3.1. Chronic Lymphocytic Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2.4. Chronic Myeloid Leukemia
4.4.2.4.1. Chronic Myeloid Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Lymphoma
4.5.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.1. Non-Hodgkin Lymphoma
4.5.1.1.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.1.2. Hodgkin Lymphoma
4.5.1.2.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Myeloproliferative Neoplasms
4.6.1. Myeloproliferative Neoplasms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.2 Polycythemia vera (PV)
4.6.2.1 Polycythemia vera (PV) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.3 Essential thrombocythemia (ET)
4.6.3.1 Essential thrombocythemia (ET) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6.4 Myelofibrosis (MF)
4.6.4.1 Myelofibrosis (MF) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Other Cancers
4.7.1. Other Cancers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Hemato oncology testing Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Hemato oncology testing Market Product Movement Analysis
5.3. Hemato oncology testing Market Size & Trend Analysis, By Product 2018 - 2030 (USD Million)
5.3.1. Assay Kits and Reagents
5.3.1.1. Assay Kits and Reagents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.1.2. Services
5.3.1.2.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Hemato oncology testing Market: Technology Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Hemato oncology testing Market Technology Movement Analysis
6.3. Hemato oncology testing Market Size & Trend Analysis, By Technology, 2018 - 2030 (USD Million)
6.3.1. PCR
6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.2. Real-time qPCR
6.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.3. Digital PCR
6.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.1.3.2.
6.3.2. IHC
6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. NGS
6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Cytogenetics
6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Other Technologies
6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Hemato oncology testing Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Hemato oncology testing Market End Use Movement Analysis
7.3. Hemato oncology testing Market Size & Trend Analysis, By End Use 2018 - 2030 (USD Million)
7.3.1. Hospitals
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Academic & Research Institutes
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Others
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Participants Overview
8.3. Financial Performance
8.4. Product Benchmarking
8.5. Market Position Analysis, 2024 (Heat Map Analysis)
8.6. Strategy Mapping
8.6.1. Mergers and Acquisitions
8.6.2. Launch
8.6.3. Partnerships & Collaborations
8.6.4. Expansion
8.6.5. Others
8.7. Company Profiles
8.7.1. F. Hoffmann-La Roche Ltd
8.7.1.1. Participant’s overview
8.7.1.2. Financial performance
8.7.1.3. Product Benchmarking
8.7.1.4. Strategic initiatives
8.7.2. Abbott
8.7.2.1. Participant’s overview
8.7.2.2. Financial performance
8.7.2.3. Product Benchmarking
8.7.2.4. Strategic initiatives
8.7.3. EntroGen, Inc.
8.7.3.1. Participant’s overview
8.7.3.2. Financial performance
8.7.3.3. Product Benchmarking
8.7.3.4. Strategic initiatives
8.7.4. Qiagen N.V.
8.7.4.1. Participant’s overview
8.7.4.2. Financial performance
8.7.4.3. Product Benchmarking
8.7.4.4. Strategic initiatives
8.7.5. Cepheid (Danaher Corporation)
8.7.5.1. Participant’s overview
8.7.5.2. Financial performance
8.7.5.3. Product Benchmarking
8.7.5.4. Strategic initiatives
8.7.6. Thermo Fisher Scientific, Inc.
8.7.6.1. Participant’s overview
8.7.6.2. Financial performance
8.7.6.3. Product Benchmarking
8.7.6.4. Strategic initiatives
8.7.7. Bio-Rad Laboratories, Inc.
8.7.7.1. Participant’s overview
8.7.7.2. Financial performance
8.7.7.3. Product Benchmarking
8.7.7.4. Strategic initiatives
8.7.8. Illumina, Inc.
8.7.8.1. Participant’s overview
8.7.8.2. Financial performance
8.7.8.3. Product Benchmarking
8.7.8.4. Strategic initiatives
8.7.9. Amoy Diagnostics Co., Ltd.
8.7.9.1. Participant’s overview
8.7.9.2. Financial performance
8.7.9.3. Product Benchmarking
8.7.9.4. Strategic initiatives
8.7.10. ASURAGEN, INC
8.7.10.1. Participant’s overview
8.7.10.2. Financial performance
8.7.10.3. Product Benchmarking
8.7.10.4. Strategic initiatives
8.7.11. ArcherDX, Inc. (IDT)
8.7.11.1. Participant’s overview
8.7.11.2. Financial performance
8.7.11.3. Product Benchmarking
8.7.11.4. Strategic initiatives
8.8. List of Other Market Players
Chapter 9. Key Takeaways